Delta Air Lines will account for 90% of EU coronavirus cases in August | Coronavirus pandemic news

[ad_1]

The European Center for Disease Control and Prevention stated that “it is very important to promote vaccine promotion at a very high speed” to prevent the spread of highly infectious variants.

By the end of August, Highly infectious Delta variant According to data from the European Center for Disease Control and Prevention (ECDC), the new coronavirus infection is expected to account for 90% of new COVID-19 cases in the EU.

The warning issued by the health agency on Wednesday echoed a similar statement made by the World Health Organization last week, which stated that the mutation originally discovered in India is now dominating the world.

ECDC estimates that the Delta variant (B.1.617.2) is 40% to 60% more infectious than the Alpha variant (B.1.1.7) first discovered in the UK, which is currently the main variant of the new coronavirus Circulate within the group.

Due to its increased spread, Delta Air Lines has become a concern for many governments in Europe, although most countries are taking steps to ease restrictions after the overall decline in new COVID-19 cases.

ECDC said: “Delta variants are likely to spread widely in the summer, especially among young people who are not suitable for vaccination.”

“If they are not fully vaccinated, this may put the more vulnerable people at risk of infection and cause serious illness and death.”

The center stated that “it is very important to promote the introduction of the vaccine at a very high speed” to prevent the spread of the variant and reduce its health impact. According to data from ECDC, so far, about 30% of people aged 80 and over in the EU and 40% of people over 60 years of age in the EU have not been fully vaccinated.

Vaccines effective against mutations: new research

Since most EU member states have not yet fully vaccinated one-third of their population, ECDC also urges countries to be cautious in relaxing containment measures aimed at limiting the spread of the virus.

The agency stated: “During the summer months, any relaxation of the strict non-pharmaceutical measures implemented in early June could lead to a rapid and significant increase in daily cases in all age groups.”

It added that this increase could in turn lead to an “increased number of hospitalizations and deaths, and if no additional measures are taken, it may reach the level of the fall of 2020”.

However, ECDC stated that two doses of the approved COVID-19 vaccine provide “high protection” against the variant and its consequences.

A new study published by Oxford University researchers in the journal Cell claims that the COVID-19 vaccine produced by AstraZeneca and Pfizer is still widely effective against Delta variants.

The scientists studied the ability of antibodies in the blood of people who received two shots of the vaccine to neutralize more infectious mutations.

“There is no evidence of widespread escape, indicating that the current generation of vaccines will provide protection against the B.1.617 lineage,” the paper said.

Last week, an analysis by Public Health England (PHE) also showed that vaccines produced by Pfizer and AstraZeneca provide more than 90% protection against hospitalization of the Delta variant.

Researchers at the University of Oxford also analyzed the possibility of re-infection in people who had previously had COVID-19.

Judging from the ability of antibodies in blood samples to neutralize variants, the risk of re-infection of Delta variants appears to be particularly high in individuals with Beta and Gamma lineage infections that were previously discovered for the first time in South Africa and Brazil, respectively.

In contrast, the previously infected Alpha variant confers “reasonable” cross-protection against all variants of interest, making it a template for shaping the next generation of vaccines.

“[Alpha] It may be a candidate for the new variant vaccine that provides the broadest protection,” the researchers said.



[ad_2]

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker